MYMD | MyMD Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.7801 - 1.8399
52 Week Range	1.7500 - 63.90
Beta	2.62
Implied Volatility	561.51%
IV Rank	65.71%
Day's Volume	22,707
Average Volume	61,809
Shares Outstanding	2,370,420
Market Cap	4,290,460
Sector	Healthcare
Industry	Biotechnology
IPO Date	2014-01-23

Valuation
Profitability
Growth
Health
P/E Ratio	-0.20
Forward P/E Ratio	N/A
EPS	-9.27
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	6
Country	USA
Website	MYMD

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

MYMD's peers: EXAI, RXRX, AVIR, UBX, ICVX, REPL, NVCT, LYRA, KRON, GOSS, REVB, YS, GOVX, NBY, XBIO, SRZN, BOLT, LRMR, KROS, KZR, LGND, PASG, ORIC, LYEL, DSGN

*Chart delayed

Analyzing fundamentals for MYMD we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see MYMD Fundamentals page.

Watching at MYMD technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on MYMD Technicals page.